REG - Haleon PLC - Board Changes

HALEONAnnouncement

05/12/2024 10:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241205:nRSE9658Oa&default-theme=true

RNS Number : 9658O  Haleon PLC  05 December 2024

 

 

Haleon plc: Board Changes

 

5 December 2024: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today
announces the following changes to the Board.

 

Following the reduction of Pfizer Inc.'s shareholding in Haleon plc below 20%,
and in line with the Pfizer Relationship Agreement with Haleon plc, David
Denton, Non-Executive Director and

representative of Pfizer Inc., stepped down from the Board on 4 December 2024.

 

Bláthnaid Bergin has been appointed as an independent Non-Executive Director
and will join the Haleon Board on 24 February 2025.

 

Bláthnaid Bergin brings financial leadership and strategic planning
experience from a variety of consumer-facing businesses. Bláthnaid is
currently the Chief Financial Officer of J Sainsbury plc, where she has played
a pivotal role in driving the company's financial strategy and operational
efficiency initiatives. Prior to joining Sainsbury's, Bláthnaid held senior
finance leadership and international positions at Aviva, RSA and GE working
across Europe, Asia and Australia. She is a Chartered Accountant. Bláthnaid
was previously Non-Executive Director, Chair of the Audit Committee and Senior
Independent Director for Artemis Alpha Investment Trust.

 

Sir Dave Lewis, Haleon's Chair commented: "On behalf of the Board, I would
like to thank Dave for his insights and contributions to the Board's
discussions. We wish him all the very best for the future. I would like to
welcome Bláthnaid to Haleon. With her strong track record of financial
leadership and transformation from multiple consumer-facing businesses,
Bláthnaid brings a wealth of relevant skills and experience to the Board."

 

The Company confirms that there is no further information to be disclosed
under the requirements of UKLR 6.4.6R and 6.4.8R.

 

Amanda Mellor

Company Secretary

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans five major categories - Oral Health, Pain Relief, Respiratory Health,
Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu,
Otrivin, Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.

 

For more information, please visit www.haleon.com (http://www.haleon.com/)
.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFSLSUIELSEDE